Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT: Bemarituzumab plus mFOLFOX6 in untreated advanced gastric and GEJ cancer (Japan)
jRCT2080224734Phase 2Completed
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Bemarituzumab + mFOLFOX6 with Placebo + mFOLFOX6 (2 arms). Started Jun 2019; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080224734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224734.